Q4 2024 Qiagen NV Earnings Call
Ladies and gentlemen, thank you for standing by I am Karen your global meat call operator.
Speaker Change: Welcome and thank you for joining Qiagen Q4, 'twenty 'twenty four earnings conference call webcast.
At this time all participants are in a listen only mode. Please.
Speaker Change: Please be advised that this call is being recorded at Qiagen to request and will be made available on their internet site.
Speaker Change: Prepared remarks will be followed by a question and answer session. If you would like to ask a question you May Press star followed by one on your Touchtone telephone.
John: Please press the Star key followed by zero for operator assistance at this time I would like to introduce your host John <unk>, Vice President head of corporate Communications and Investor Relations at Qiagen. Please go ahead.
Speaker Change: Thank you operator, and welcome to all of you to our quarterly results call. We appreciate your time and interest in Qiagen on the call today are Terry Bernard our Chief Executive Officer enrolling Soccer's, our Chief Financial Officer also joining us is Dr. Dominican Marturano from our IR team. This call is being webcast live and will be archived in the IR.
John: Section of our website at Www Qiagen Dot com.
John: A copy of the quarterly results press release and the presentation are also available on our website.
John: Before we begin I'd like to remind you that this call will include forward looking statements actual results may differ materially from those projected due to various factors. These risks and uncertainties are outlined in our most recent form 20-F filed with the FCC and its available on our website. Additionally, we will refer to financial measures that are not prepared in accordance with.
John: U S generally accepted accounting principles or GAAP. These non-GAAP measures provide useful insights for investors and a reconciliation to the most directly comparable GAAP figures is included in our release. Please note that all references to earnings per share refer to diluted EPS with that let me hand over the call to Terry.
Thanks, a lot John and Hello, Good morning, and good afternoon or good evening, depending on where you are in the world and thank you all for joining us.
Terry Bernard: I am very pleased to share that Qiagen has once again delivered a strong performance in the fourth quarter.
Terry Bernard: Closing out 2024 on a strong note.
Terry Bernard: Our results reflect both the resilience of our business and the trust of our customers reinforcing our momentum.
Terry Bernard: As we move into 2025.
Terry Bernard: We exceeded the targets for sales and adjusted earnings.
Terry Bernard: We are again, among the fastest growing companies in our industry.
Terry Bernard: Those results reflect the strength of our portfolio.
Terry Bernard: With over 85% of our sales coming from highly recurring revenues.
Terry Bernard: They show as well our ability to deliver solid profitable growth in two days challenging and volatile environment.
Terry Bernard: I would like to take a moment to recognize a fault silver with teams who have been instrumental in delivering those achievement.
Terry Bernard: And I would like also to acknowledge the impact of our customers, whose work continues to advance science and improve health care across the globe.
Terry Bernard: These being said let.
Terry Bernard: Let me know highlight our key messages.
Terry Bernard: First we exceeded our outlook for Q4, two 424 in both Knits says.
Terry Bernard: Adjusted earnings.
Terry Bernard: Net sales were 521 million in the fourth quarter growing 3% C E R and shift plus I think our outlook for at least 520 million she Ara game.
Terry Bernard: Sales for our core business were up 4% CER when excluding discontinued products.
Terry Bernard: In particular, our junior mortgage and I Gotta do nooks systems.
Terry Bernard: Adjusted diluted EPS was <unk> 61 cents C E are exceeding our target of at least 60 cents C E R.
Terry Bernard: For the full year two falls on them 24, we also exceeded our outlook for at least 1.985 billion C. E. R. In net sales.
Terry Bernard: And the latest upgrade.
Terry Bernard: Our adjusted EPS outlook for two door, Laos, and 19 cents C E R.
Terry Bernard: Second we reached key milestones across our portfolio.
Terry Bernard: What was he shouldn't even our company to deliver solid profitable growth towards our 28 targets.
Terry Bernard: First I just thought diagnosed he had a very very solid year with 25 C E. Our growth in Q4 and over 660 new system.
Terry Bernard: This meant in two folds in in 'twenty for this exceeded our targets.
Terry Bernard: Our teams achieved FDA clearances for full panels for use for the Syndromic testing system during 2024.
Terry Bernard: No we have the full menu for the very important U S market. We spun is covering the detection of many respiratory.
Terry Bernard: Gastrointestinal and meningitis encephalitis conditions.
Ken: Hey, Ken.
Terry Bernard: Quality feeling gee.
<unk> 10 standout test for latent tuberculosis delivered 14% growth in Q4, and 11% CER growth for the year on gains in all regions.
Terry Bernard: And just underscores the increasing adoption.
Terry Bernard: This solution worldwide.
Terry Bernard: We continue to see ample room for quanta to grow.
Terry Bernard: Given that only about 40% of the global latent TB testing market east converted to blood based testing.
Terry Bernard: So we continue.
Terry Bernard: And to execute on our clear strategy to drive further conversion.
Florida, where at least center in the U S. For example, the recent shoebill kudos he's our braking concepts reminds us that this is a global epidemic.
Terry Bernard: Also impacting the most developed countries.
Terry Bernard: To put this in context.
Terry Bernard: Sars outbreak is the largest document at the case of these potentially photo fatone.
Terry Bernard: Bacterial disease since the C. D C began counting cases in the fifties.
Terry Bernard: Once again this shows that you built your doses might be silent Betsy it's everywhere.
Terry Bernard: Great.
Terry Bernard: Moving to digital PCR our teams expanded the capabilities of the carrier Cui T system with the launch of our Carryout Koichi diagnostic.
Terry Bernard: For clinical use.
Terry Bernard: Here, we are focusing on oncology and infectious disease applications.
Speaker Change: While also building on great Joe Ritchie decision.
Speaker Change: Over the two folds on 700 cumulative catch equity placements since launch.
Pope.
Speaker Change: Our sample technologies portfolio.
Speaker Change: We achieved a significant milestone with over a thousand cumulative placement of our new easy to connect automated sample preparation instrument.
Speaker Change: We continue.
Speaker Change: Leading in automated sample pro six easing as we capture opportunities in high growth areas like liquid biopsy.
Speaker Change: Minimal residual disease or microbiome as well.
Speaker Change: Our third key message for today.
Speaker Change: We continue to make significant improvements in profitability and free cash flow.
Speaker Change: In Q4 of two 424.
Speaker Change: Adjusted operating income margin rose by 2.6 percentage points.
Speaker Change: And achieve 30.6% offsets.
Speaker Change: This was driven by efficiency gains across the business and obviously the decision to phase out the new mud system by mid 2025.
Speaker Change: For the full year two fold in in 24 hour adjusted operating income margin came in at 28, 7%.
Speaker Change: We also generated extremely strong free cash flow of 506 million in 2024 D. C is up 63%.
Speaker Change: Compared to two folds on in 'twenty three.
Speaker Change: Those results demonstrate again, our ability to deliver growth and improve shareholder returns.
Speaker Change: As you have seen recently.
Speaker Change: Early 2025, we completed a new synthetic share repurchases of approximately $300 million.
Speaker Change: Building on the $300 million, we all read you returned to shareholders early two falls around 24.
Speaker Change: This once again.
Speaker Change: We reaffirm our commitment to return at least 1 billion.
Speaker Change: Shareholders by the end of 2028 and that of course, as we said in New York 24.
Speaker Change: He's a scent of significant M&A opportunities.
Lost.
Speaker Change: We are focusing on delivering on our two folds on 25 outlook.
Speaker Change: Which is clearly aligned with our path to our to achieving our 2028 goals.
Speaker Change: Well to 425, we.
Speaker Change: We expect net sales to grow by approximately 4% C E R.
Speaker Change: And more important to us.
Speaker Change: To raise about 5% C E are in our core portfolio.
Speaker Change: She's once again, excluding discontinued product.
Speaker Change: Like pneumonia.
Speaker Change: Adjusted diluted EPS is expected to be at least at $2.28 C. R.
Speaker Change: Those targets are really back to better our plants to make progress in developing and commercializing differentiated portfolio.
Speaker Change: We continue to see significant opportunities ahead for Qiagen.
Speaker Change: As we target key markets to develop and maintain leadership positions.
Speaker Change: D C is really pushing goes.
Speaker Change: On a course to achieve our midterm targets for 2028.
Speaker Change: They all come down to seven.
Speaker Change: 51, two and one.
Speaker Change: The 7% sales Guy go for 24 to 28 from our core business, excluding discontinued products like Nordics.
Speaker Change: The 31% adjusted operating income margin by two fold in in 'twenty weight.
Speaker Change: And we are very well on our way to achieving this.
Speaker Change: With $2 billion Upsells from our group of girls pillows.
Speaker Change: Which two guys are already you achieve $1.4 billion of cells into falls on them 24.
Speaker Change: And at least $1 billion in return to shareholders and we have already completed $600 million of that Gordon.
Speaker Change: I would like now to hand, the whole virtual hurdle for a review of our financial results.
Speaker Change: Thank you Teri Hello, everyone sensuous vote for me for joining I'll call. It. We are pleased specific results for the fourth quarter and for full year 'twenty fall. So let me highlight a few key figures.
Speaker Change: Results for the second half of 'twenty for sure 4% C. Our tour growth along this 5% CR Wolf with our core business that excludes discontinued products.
Speaker Change: Adjusted operating income margin in 'twenty, four 'twenty at probably 7% representing an increase of 1.8 percentage points from 'twenty to 'twenty three S. We set a goal of at least 150 basis points of margin improvement in 25 to move above 30% for full year.
Speaker Change: 63% increase in free cash flow for 24 to five 6 million U S dollars.
Speaker Change: This was clearly put us on a strong cost to deliver our commitments for 2025.
Speaker Change: It's all of them for 25 is clearly aligned with our 28 targets for solid profitable growth.
Speaker Change: Let me now give you some additional insights into our results and sales trends from the fourth quarter and for the full year 'twenty four.
Speaker Change: Among the product groups, we saw solid COVID-19 diagnostic solutions, along with single digit CER gains in PCR and genomics.
<unk> technologies sales declined slightly in the fourth quarter 'twenty four as higher demand for consumables used on our lines to medicine forensics applications was offset by weaker instrument sales.
Speaker Change: The full year to see percent CER decline in Sop protects the Arctic cuda to lost headwinds from the pandemic and anticipate a speak to low single digit CAGR Wolf in 2025.
Speaker Change: Important draw a bit cough strategy is increasing the use of kits on the increasing installed basis of qiagen instruments.
Speaker Change: We are preparing three important new sub protect system launches over the next 24 months and this will help to enhance midterm growth.
Speaker Change: The diagnostic solutions sales grew 10% see out in the fourth quarter and were up 12% CER excluding <unk>.
Speaker Change: As he mentioned earlier, a key driver of us or quantify what to be tests, delivering 14% CER sales growth in Q4, as we saw solid growth in all regions.
Speaker Change: Can I ask about the ex called 25% CER driven by double digit growth in both consumables and instrument sets to support.
Speaker Change: First of all growth for at least six of that new system placements in 'twenty four reaching all of our 4600 cumulative placements since launch.
Speaker Change: It's a P. C. R product Coupe said school Super said see let back of jewelry for the kayak purity digital Pcr system.
Speaker Change: In fact cause you have it's for US a cadre of acuity shift the other just to see our growth as we added over 100 U S is for use of this system and large jakaya acuity K acuity explosion for clinical applications.
Speaker Change: Like others, we continue to see cautious spending by customers that new instruments.
Speaker Change: We continue to have confidence in the midterm growth opportunities given the advantages of digital PCR or was a predecessor generation of PCR and next generation sequencing.
Speaker Change: Is it genomics and yes product group sales grew 2% and see all the fourth quarter supported by growth.
College of digital it's a business as well as gains in sales of your other consumer goods used under third party I just systems.
Speaker Change: The performance of Judy I was driven by growth in the clinical portfolio and just what does it offset a modest decline in the discovery portfolio.
Speaker Change: As we have noted drugs a year. So it was odds for acuity I had 24 were adversely impacted by the ongoing transition to a SaaS software as a service subscription model, particularly the pharmaceutical sector from lung got dropped licensing agreements.
Speaker Change: He sees this position continuing drawing twenty-five as he walks through converting the remaining licensing agreements into the SaaS model.
Speaker Change: Taking a look at our pillar as a group. These are kind of acuity chaos that to X QD I sought to technologies and quantify everyone sees delivered combined sales of one Pud suite 9 billion U S dollars and 24.
Speaker Change: Aggregate was 99, plus 3% of our target for the year. So we are moving in the right direction towards our goal for at least $2 billion from our golf fill us in 28.
Speaker Change: It's not moved towards that supposed to regions, where we are sharpening our commercial concentrations with specialized and empower teams focused on the Americas, EMEA and Asia Pacific Japan.
Is it Europe Middle East Africa regions sales was 4% CER.
Speaker Change: The top performing countries, including France, Italy, Spain, and Switzerland.
Speaker Change: Also in countries like Saudi Arabia, it's United Arab Emirates.
Speaker Change: Is that Americas sales was 5% see a what was the fourth quarter of 'twenty three with solid cool is a key market observations.
Speaker Change: I did state, Canada, Brazil and Mexico.
Speaker Change: The Asia Pacific, Japan region sales were down 5% C. I the fourth quarter and this was slightly better than the full year decline of 7% C. L.
Speaker Change: China sales declined at a lower low teens see I'll wait for the fourth quarter over the year ago period, and this mirrors the decline for the year.
Speaker Change: We continue to take a cautious view on predicting a pasta market that cowboy in China, which is moving to less than 5% of toy sales.
Speaker Change: Five.
Speaker Change: Let's now review the rest of the income statement for the fourth quarter.
Speaker Change: As I mentioned earlier adjusted operating income rose, 12% to 159 million U S dollars. As a result said adjusted operating income margin improved by 2.6 percentage points to Saudi 0.6% over the fourth quarter of 2023.
Speaker Change: This results underscore our commitment to solid profitable growth as we look for additional operating margin gains and 25, and we could reach our 31% target earlier than 'twenty five 'twenty eight.
Speaker Change: Adjusted gross margin improved to 67, 1% of sales from 65, 7% in Q4, 'twenty suite, an increase of one four percentage points and the key driver for the overall again as adjusted operating income margin.
Speaker Change: A big contributor of US again chaos that to X a 'twenty saw during 'twenty for this product had a favorable impact on the consumable product mix and we also had benefits from higher production capacity utilization.
Speaker Change: Additional contributions came from the softer technologists consumer goods business and kind of acuity digital P. C L.
Speaker Change: We also saw you saw benefits from the decision to discontinue in Nordics and more benefits too.
Speaker Change: To come in 'twenty five.
Are the investments, we're not put 3% of sales up slightly from 9% in the fourth quarter 'twenty three if.
Speaker Change: We have generated benefits from the Nordics decision why the web pick up programs in other areas. Our target remains four onto your investments at about 9% to 10% of sales.
Speaker Change: Marketing expenses declined about one two percentage points to 21, 8% of sales. He has he saw the benefits of our efficiency programs, while increasing our digitization initiatives with over 60% of sales currently going through digital channels.
Speaker Change: General and administrative expenses declined to five 3% Upsells from five 6% in Q4 'twenty suite S. We maintain a high level of I T and cyber security investments combined with efficiency gains.
Speaker Change: Regarding there was talk Shang Fung boutiques and related projects being cut about 20 months $21 billion of the charges in the fourth quarter in line with our target for about $20 million to $25 million for this period.
Speaker Change: Some remaining charges may come in the first half of 'twenty five as we complete the program in lab as a target for about $4 billion of charges. In total advisory noted that's the vast majority are noncash items.
Speaker Change: S. We also set about how did that billion dollars I expect it to be cash charges of which we had grown $30 million and expect about $70 million and.
Speaker Change: And 25.
Speaker Change: For the full year. The adjusted operating income margin was 28, 7% an increase of one eight percentage points from 26, 9% in 'twenty three.
Speaker Change: Again, we have reinvested some of the benefits from our efficiency programs into targeted growth opportunities. While also seeing initial contributions from the decision to discontinue in the Library X.
Speaker Change: As for the adjusted EPS, So does ours for the source fourth quarter of 'twenty 461 cents at all it's a 61 cents at constant exchange rates. This was ahead of our target for at least 60 cents Etsy. Yeah. In fact, we were able to steadily increase our outlook during the course of 'twenty four.
Speaker Change: And we achieved $2 20 sets at sea all compared to the initial targets at $2.10 C E O.
Speaker Change: Turning to cash flow, we delivered strong improvements during the course of 'twenty for operating cash flow was 47% to $674 million from $459 billion in 'twenty three mainly due to reduced working capital requirements. We achieved this growth.
Speaker Change: Even after absorbing payments related to the restructuring decisions advanced in 'twenty four.
Speaker Change: Saw a steady improvement in working capital during the course of the year.
Speaker Change: This fell by about $282 million in 24 to five 6% of total assets at the end of 'twenty four compared to nine 8% at the end of 'twenty three.
Speaker Change: Our conscious fuel spreads are also contributed to the improved cash flow and stood at $55 six days at the end of 'twenty four.
Speaker Change: And now that contribution factor was the reduction in inventories, which decreased to 193 days at the end of 'twenty four from 214 days at the end of 'twenty three.
Speaker Change: Cash flow was at an even faster pace said operating cash flow increased 63% to $506 million for the year over.
Speaker Change: 'twenty suite. This is particularly impressive given the higher level of Capex spending of 24 over the year ago period, mainly due to the upgrade of our S&P system.
Speaker Change: So we are very pleased with a solid cash flow results were 24, and I'm looking forward to another year of solid results and twenty-five we said I would like to hand back to Teri.
Terry Bernard: Thanks, Rocco and Uh huh.
Teri: Let's spend some time to discuss it would be some progress our teams have made across the overall portfolio of products. Starting first we sample technology as we have highlighted at the beginning of the school carrier Didnt have surpassed over a thousand placement of easy to connect automated sample preparation instrument.
Teri: System easy to connect is unlocking new possibilities across diagnostic genomics cancer research epidemiology and forensics as well.
Teri: As we continue to drive laboratory automation, we placed more than.
Teri: 1800 sample prep instruments in 2024.
Teri: And that's what I'll say looking ahead, we are planning to launch free new sample prep system by the end of 2026.
We are also strengthening our microbiome and liquid biopsy consumables capabilities with the launch of two new sample kits.
Teri: Those advancements are opening up new frontiers for precision medicine, and a further cementing our leadership in automated sample prep market.
Teri: Moving to quantify them.
Teri: The market, leading test for latent TB okey-dokey detection.
Teri: We said before Jubail kudos he's he's still on the rise not just in Kansas notices in all other areas of the U S. Not just in Europe, but.
Teri: But across the entire world.
Teri: Despite global progress one in four people in the world carries latent tuberculosis and skin test and then T. Cui teach solution still account for 60% of testing in.
Teri: Creating a significant market conversion opportunity for quanta you feel.
Teri: At Qiagen, we continue to be committed to expanding access to testing it as part of the global four two and the tuberculosis epidemic by 2035.
An example.
Teri: In 2024, we expanding screening of walnuts through our partnership with the International panel physician Association in the U S, which is critical for switching immigration screening standouts.
Teri: Additionally, we secured new American guidelines, allowing for the use of quantity or interesting children of all ages and these expanded our potential group of patients for conversion from the skin test.
Teri: Beyond latent TB.
Teri: We are still preparing to launch the Lyme disease test in partnership with <unk>.
Teri: We continue to invest in a carrier reached quantifiable solution for emerging market.
Teri: Turning now to chaos taught our syndromic testing solution that continues to expand its impact globally.
Teri: You have seen.
Teri: We recently received FDA clearance for the chaos that G. III gastrointestinal panel, many b N V and the B N V. Here, I mean testing for bacterial and viral load conditions.
Teri: These mini panic.
Teri: <unk> is designed to support outpatient diagnostic for five coburn bacterial and viral infections.
Teri: And those are tests for G. I that will just this time focus on five bacteria or conditions.
Teri: Has been submitted and is awaiting FDA clearance.
Teri: Those developments in 2025 drilled on a strong year of Okay. You start with four syndromic panels, receiving FDA clearance in 2024.
Teri: We are now offering a very comprehensive U S test portfolio for respiratory Gi meningitis conditions.
Teri: It's really about who knows there are significant milestones as we continue to expand the footprint of carrier starts on the Syndromic testing market.
Teri: As you have seen last year.
Teri: Beyond even fixtures disease diagnostic we also advanced companion diagnostic securing partnership with Eli Lilly, either time or disease or astrazeneca in chronic diseases.
Teri: Looking ahead in 2025 and beyond the focus remains forecast start on expanding the portfolio the menu and therefore the market reach.
Teri: We therefore plan to introduce a new chaos that patent in Europe for blood culture testing, including pathogens that can cause sepsis.
Teri: In the U S. In 2025, we do plan to complete two submission.
Speaker Change: D. G. I mean, he pattern that I just talked about.
Speaker Change: And again, the blood culture of panel testing among ozone pathogen for some that are causing sepsis.
Speaker Change: At the same time.
Speaker Change: Our team all over the World continued to work on our current installed base of more than 4600 system.
Speaker Change: And still the majority of those system are outside of Michigan.
Speaker Change: Meanwhile.
Speaker Change: We are advancing our high throughput strategy with the caveat that rice your statement.
Speaker Change: After a successful launch in Europe in 2022, we are now preparing for the launch of the solution in the U S.
Speaker Change: Cause you Shouldnt Ngos to enter the high throughput market and therefore drive further adoption of Syndromic testing.
Speaker Change: Moving now to catch up quickly our digital PCR platform.
Speaker Change: Which continues to push the boundaries of precision and performance.
Speaker Change: In the fourth quarter of 2024, we took a very significant step forward by expanding cat treaties multiplexing capabilities from five to 12 targets per sample.
Speaker Change: This is extremely important in helping our customers to advance their use of application in translational research microbiome analyses pathogen detection of cell and gene therapies.
Speaker Change: Okay equity adoption continues to accelerate.
Speaker Change: And we increasingly believe in the midterm potential of this breakthrough digital Pcr system.
Speaker Change: As you have seen in 2024, we have also launched our CAG diagnostic, bringing digital PCR into the clinical world.
And we also expanded our assay menu.
Speaker Change: Introducing over more than 200, new digital PCR assays.
Speaker Change: Looking ahead, we plan to expand the menu with at least a game.
Speaker Change: 100 additional assays in 2025.
Speaker Change: We are now focusing on cell and gene therapy, and Petros and research.
Speaker Change: Closing with Q D I b.
Speaker Change: <unk> digital insight.
Speaker Change: Bioinformatics business continued to enhance the power of next generation sequencing data.
Speaker Change: In 2024, we enhance our a I driven bioinfomatics with their new AI extension for ingenuity pathway analysis that is designed to streamline complex molecule analysis.
Speaker Change: We also strengthened our road and clinical genomics through for example, our collaboration with General mix, England on degeneration study.
Here, we are supporting other scared of an entire country G analysis and interpretation of more than 100000 newborn genomes to screen for more than 200 genetic conditions.
Speaker Change: In 2024 25 for the eye.
Speaker Change: We continue to plan to launch new AI driven application.
Speaker Change: All part of our plan to expand our portfolio to over 14 AI enabled solutions by 2028.
Speaker Change: And now we're back to around for some details on our outlook 2025.
Speaker Change: Thank you Terry let me now provide more perspectives.
Speaker Change: Perspectives on our updated outlook for 'twenty five and also for the first quarter.
Speaker Change: Ambition is to generate another year of improved operational profitability as we execute on our commitment to solid profitable growth.
Speaker Change: We have initiated our full year outlook for 'twenty five four sets over about 4% CER, which reflects 5% CER growth in our core business. We are expecting an exploration of a full year 'twenty four.
Speaker Change: Where we had a core growth rate of 2% yeah.
Speaker Change: And adjusted earnings per share outlook for 'twenty five is for at least $2.28 Etsy yeah.
Speaker Change: This reflects about 9% see our growth in adjusted EPS to about $2 37 said see are driven by the operational business expansion, which includes about two cents of accretion from the share repurchase.
Speaker Change: On the other hand external factors presented a headwind of approximately five said see a primary due to lower adjusted net interest income compared to 24 and anticipated increase in the adjusted tax rate for 25.
Speaker Change: For the first quarter of 'twenty five we have set the outlook for net sales growth of about 3% CER from sales of $459 million in the first quarter of 'twenty fall just translate to 4% CER growth in the core business.
Speaker Change: We are taking a balanced view on the challenges and opportunities the current microenvironment.
And our target for adjusted unexplored.
Speaker Change: First quarter is for at least 50 cents per share also at C. O. So another good improvement although results of 46 cents in the first quarter of 'twenty four.
Speaker Change: Let me also provide some perspective on the currency trends against U S. Dollar for the full year of your currently expected adverse impact upsets or about two percentage, but at about two to three cents and adjusted EPS results and for the first quarter. The currently expected adverse impact on sales of about two percentage points at about one sitting on adjusted EPS results.
Speaker Change: I would like now to hand back to tea.
Thank you all we are coming at the end of our core and before the Q&A, Let me summarize our key messages for today first we delivered again a strong performance in Q4, 'twenty four exceeding our outlook for both net sales and adjusted earnings.
Speaker Change: Once again those results are positioning our company.
Speaker Change: As one of the fastest growing company in our industry.
Our havey the recurring revenues.
Speaker Change: Making up over 85% of our sales continued to drive growth even in a challenging macro environment, we scotia's customer spending one is three months.
Speaker Change: We were extremely pleased with.
Speaker Change: With the strong contribution from our diagnostic solution led by quantifying Your studies I was worried about yet where growth in our PCR and genomics.
Speaker Change: Those six issues along with efficiency gains drove a higher adjusted operating margin of 36% and very solid improvement.
Speaker Change: And cash flow generation.
Speaker Change: For the full year, we achieved our targets for total net sales operational profitability and product development milestones, while delivering another year of outstanding cash flow.
Speaker Change: <unk> continues to deliver.
Speaker Change: This gives us confidence.
Speaker Change: That we can achieve our goals for 2025.
Speaker Change: Plus you shouldn't carry adjourn for solid profitable growth in the years ahead.
Speaker Change: We even believe.
That should that work environment become less volatile.
Speaker Change: This outlook to 425, Oh for some potential for upsides.
Speaker Change: Before ending the call.
Speaker Change: I would like to let you know that we will be having more V T or deep dive session in 'twenty five highlighting our graph killer.
Speaker Change: We received excellent feedback on our inaugural deep dive on the Q D I business in December.
Speaker Change: And we want to continue and keep that format going into 2025 with that thanks, a lot and handing back to John and the operator for Q&A session. Thank you.
Speaker Change: Ladies and gentlemen at this time, we will begin the question and answer session.
Speaker Change: One who wishes to ask a question May press star followed by one on their Touchtone telephone.
Speaker Change: If you wish to withdraw your question you May press star followed by two.
Speaker Change: To ensure we can accommodate as many people as possible. Please limit yourself to only one question and if necessary one follow up.
Speaker Change: <unk> will also be muted after finished asking the questions.
Speaker Change: Anyone who has a question May press star followed by one at this time.
Speaker Change: One moment for the first question please.
Speaker Change: The first question comes from Tycho Peterson of Jefferies. Please go ahead.
Speaker Change: Hey, Thanks first question on quantity, Iran.
Terrific growth there are you kind of willing to underwrite double digit growth. This year and then obviously you got to keep patent win in the German courts earlier this week.
Speaker Change: Actively block newer entrants from the EU and then the second question is just on kind of acuity and some of the pharma traction I think was at 12 Plex launch here, maybe taking more share from and he asks can you just talk a little bit about.
Speaker Change: The sustainability of that and when you think instruments overall may pick up for pay acuity. They are a little soft in the quarter.
Speaker Change: Thanks, Tycho and a very quickly yes, I mean that we are extremely pleased with the double digit performance of course, you feel warrant gains of 24.
Speaker Change: There are example of.
Speaker Change: The performance and positioning of the solution is.
Speaker Change: During the quarter at above 100 million dollar revenues.
Speaker Change: And therefore, indeed to your point, we are forecasting a double digit growth. This year is when low double digit but this is what we want to execute.
Speaker Change: Now as far as the IP. The recent press release from Qiagen is just showing that we have a strong IP and we really want to execute on it.
Speaker Change: Okay, Yeah Cui teeth.
Speaker Change: We have been saying for the last two years that we believe that this unique solution because of its differentiation.
Speaker Change: Automation.
And.
Speaker Change: Cost of ownership for our customers.
Speaker Change: His position he qiagen to become the number one in digital PCR.
Speaker Change: The 12th Flex solution.
Speaker Change: He's helping.
Speaker Change: Like <unk>.
Speaker Change: Increasing the menu for life science customers is definitely helping.
Speaker Change: Like introducing that solution into the clinical world. He's also the affinity.
Speaker Change: We are really on our way to execute on our target of $250 million revenues for digital PCR by 2028.
But not lease cycle, we acknowledge and full transparency.
Speaker Change: That's yes, we were impacted by a softer capital expense.
Speaker Change: Context in many labs, especially life Science labs.
Speaker Change: But let's also consider Fox.
Speaker Change: In Q4, Okay. Yes, it has been able to put once again more than 200 digital PCR system on the market that shows the strength, despite the difficult environment of that solution.
Speaker Change: The next question comes from the line of Michael Ruskin with Banc of America Securities. Please go ahead.
Speaker Change: Great. Thanks.
Speaker Change: I'm going to ask both upfront first is just something you just touched on at the end there in terms of the market conditions in 'twenty for how that impacted kind of acuity I just want to get a sort of a big picture view your thoughts on how that trends into 2025, I mean, especially on the instrument side. No. You don't have a lot of exposure there, but that's why you saw some of the weakness this past year.
Speaker Change: Just any early indications of maybe just an update on what your expectations are for that instrument capex spending from pharma throughout this year, you know expectations for improvement or anything like that that'd be helpful. And then second question would be.
Speaker Change: On the margins.
Speaker Change: You're talking about over 30% operating margin in 2025 really nice step up she usually that's a combination of both new biotics and just efficiency gains. So maybe you could expand on that a little bit, but also you reaffirmed 31% greater than 31% in 2028. So your 30 in 2025, so just.
Speaker Change: Is there any reason that it can't be significantly above that just seems like you're only giving US 100 bps for the next three years, just unpack that a little bit of longer term margin trajectory. Thanks.
Speaker Change: Our two first question, Mike and I will let her know answer on the margin and give you is our view on our potential of her upsides, there as well, but first on the market condition.
Michael Ruskin: Michael I always repeated the same we always repeated the same for the last four years.
Speaker Change: Just from them and tours of our markets.
Michael Ruskin: Both clinic order.
Michael Ruskin: And research or academia.
Michael Ruskin: I'll cede very solids for many reasons that we covered in the past the aging population increasing the power of technology, increasing application microbiome liquid biopsy minimal residual disease, the fundamentals of what he's really under control.
Michael Ruskin: Okay, Yeah, James I'll very solid.
Michael Ruskin: I'm more worried than they more concerns by the challenging volatile political or financial environment.
Michael Ruskin: And this what is driving that.
Michael Ruskin: What are some of your some time off considering like a cautious guidance for 2025, I still believe that achieving 5%.
Michael Ruskin: Gross sales in our core business, excluding <unk> would be a very solid performance and one of the best of the market.
Michael Ruskin: But we have said also in 2024.
Speaker Change: Yes, we were like many other companies impacted by your kind of sluggish capital expense environment in many doctors, especially life science. We explained that this was probably driven by the fact that in 'twenty for more than 50% population.
Michael Ruskin: <unk> of the population in the world wasn't their election, he's always creates uncertainties.
Michael Ruskin: Therefore, we said that we see capital expense in labs normalizing progressively Easter.
Michael Ruskin: Especially starting in H two of 2025.
Michael Ruskin: We always said as well if this is taking more time that might create some delays for carrier James but the fundamentals of the growth. After you did there.
Michael Ruskin: So that's what I can see them they confirm that that that statement now we're moving on the margin and the margin potential I hand, it over to Adam.
Adam: Yeah. Thank you to you and Hello, Michael.
Adam: As I said before it's clearly are seeing a strong commitment of qiagen to prove profitable growth and as you said before there'll be a it was about 80 basis points for last year. It will be at least had about 50 basis points for this year. So clearly go nicely on a three basis points on the 24 months.
Adam: This.
Adam: I think it's important to know and I think that's it for a very valuable at the question you asked that the Polyone are at 45% offset our margin improvement for the two year period is driven by the Nordics.
Adam: Decision.
Adam: Majority is actually coming from quite a number of efficiency projects, we're doing within the company plus of course, the underlying improvement in gross margin.
Adam: <unk> for car Qiagen, which you believe is going to continue.
Adam: It's also important to realize that we do believe that's a margin improvement does not stop and twenty-five realize I believe that we have a very solid track record.
Adam: I'd pause in front of us to improve margins significantly even beyond set and if we are going down and the revenue growth rate as you plan to do I do see any reason that it shouldn't be a double digit operational profit.
Adam: Improvement also beyond 'twenty, five and I do think it's even more important or as we said before unfortunately and twenty-five some ups external factors are most likely broke against that on interest weighed in on tax rate I would consider smaller one offs for 25. So it should also dropped down to EPS, starting in 'twenty six and beyond.
Speaker Change: Well move to our next question from Patrick Donnelly with Citi.
Patrick Donnelly: Hey, guys. Thank you for taking my questions maybe.
Speaker Change: Maybe on the debt.
Speaker Change: With you upfront as well maybe first role.
Speaker Change: Jerry sample check it seems like the guidance for flattish growth.
Speaker Change: With 25 can you just talk about what you're seeing there.
Speaker Change: Obviously, a large part of the business hasnt been the growth.
Speaker Change: Just want to talk through the moving pieces in the right way to think about that one going forward and then the second would just be around some of the administration changes here any implication that you guys have seen to start the year, whether it's U S. A.
Speaker Change: Academic.
Speaker Change: Or on the China side, it would be helpful to talk to those people.
Speaker Change: Thank you guys.
Speaker Change: Thanks, Patrick and obviously you've.
<unk> heard on wants to chime in feel free but on the central to that guidance that we didn't see some toothing Patrick.
Speaker Change: Our strategy for the last four years is really to.
Speaker Change: Invest into automated center tick.
Speaker Change: Is why we are continuing to take market share, which is why we are.
Speaker Change: Strengthening of our leadership in.
Speaker Change: And if you look.
Speaker Change: The growth pattern throughout our portfolio.
Speaker Change: Manual automated into Falcon in 24, you see that automated sample techies growing in 2024, and he sees that were a bit.
Speaker Change: And therefore.
Speaker Change: We continue to invest into Autonation, we sit today and we confirm that we we'd be launching three new instrument.
Speaker Change: In the coming two years at the end of 2025, you will see the succession of their leading central take you sort of mentioned the market, which is guessing funny, we call itself. Okay. That's.
Speaker Change: And finally connect.
Speaker Change: Early 2026, we will launch our high throughput.
Dmitry: Dmitry it system, we call it K S print.
Speaker Change: And.
Speaker Change: Around mid 2026, we we don't you're very small throughput bench stope, one shot sample thick system, we could it carry I mean.
Speaker Change: So 25 is a year of transition.
Speaker Change: The decision on menu or sample thick continuous growth on automated.
Speaker Change: And we used the launches of their new instrumentation I believe that we are on our way to execute on the guidance. We gave for central take for the 2020 for 2028 carrier.
Speaker Change: Moving to the political environment or what you're qualified the administration change.
Speaker Change: I'm really calling for keeping a cool head we continue to believe that it's too early to judge.
Speaker Change: <unk>.
Speaker Change: We are in the changeover in administration.
Speaker Change: Many of the decision that had been taken by G.
Speaker Change: Trump administration of classical decision either transition.
Speaker Change: So pick some expenses wait and see putting in place the new people, it's far too early to say that our many budget we'd be good forever by the way. If you look at the first President Trump administration, there's significant budget like DNA, Yes, Bridget oz.
Speaker Change: She stay magically and every year increase in these first two.
Speaker Change: China.
Speaker Change: You know Gary agendas are small or read it or relatively small exposure to China, it's between five and 6% of our business.
Speaker Change: We always said over the last three.
Speaker Change: Yes.
Speaker Change: But we do not believe that the Chinese market with bonds back before 2026.
Speaker Change: We can see the China.
As too big of a market and the potential to be ignored.
Speaker Change: But too specific of a market.
Speaker Change: And two let's say.
Speaker Change: Did you catch it to local champions.
Speaker Change: To become a focus of investment.
Speaker Change: We don't believe that you see is going to change in 2012 for 25 and default on China, We plan on the.
Speaker Change: When they get to even slightly negative to flattish growth.
Speaker Change: So how long would you like to add something.
Speaker Change: That's probably a bit on the European perspective.
Speaker Change: As you know, there's clearly Oh I.
Speaker Change: I would say well, it's a momentum Germany in few weeks as an election, but if you go to for example, here, Germany to the programs Oh, the major parties, there's clearly always in Quad innovation focus. So I would assume also once we have here is a clarity and again elections are down to three weeks here I.
Speaker Change: I really do think that there's some ups is a wait and see alternatives, particularly on the capex side, its not a consumable topic.
Speaker Change: But well.
Speaker Change: Get into a more supportive environment.
Speaker Change: The next question comes from Doug Schenkel of Wolfe Research. Please go ahead.
Doug Schenkel: Good day, everybody. Thank you for taking my questions I have two first what are your growth assumptions by end market in 2025, essentially what's embedded into guidance and then secondly, if market conditions become more challenging do you have the levers available to protect 150 basis points of margin expansion that you're.
Speaker Change: We're targeting.
Speaker Change: And Conversely, if the top line is better than expected should we expect margins to go higher whether you let it flow through thank you.
Doug Schenkel: Doug Thanks for the two questions I think we can take those two question the two of US who aren't on the.
Speaker Change: And market.
Speaker Change: We still believe as I said, the five minutes ago that the fundamentals of our market the diagnostic and the research market are very solid for the reason that you explained I still believe that we are in the recovery process. Because we are expecting capital sales to accelerate I said before that I see that in H two.
Speaker Change: Of 2025.
Speaker Change: And so.
The market I think Eastbourne seek back progressively and seeing your market growth at the moment.
Speaker Change: Between the 45% I think it's a reliable number.
Speaker Change: If growth happens clearly as I said before if our environment. The political financial volatility is getting clarified I said at our guidance 2025 or fill some potential for upsides, but we first need to execute on that will correct.
Speaker Change: Our guidance for 5% of core and four to 28.
Speaker Change: E P S. Yeah, but could also expand on the potential for margin expansion, depending on the market condition.
Doug Schenkel: Yeah, Hi, Doug.
Speaker Change: I do think the best way to answer your question is actually just reference what we did in the past and I think if you go look backwards and I know that your father and Kai as you know for quite some time as you can view all of this had the benefit of our cost structure being quite valuable and zeff Ov are very typically for all of us to live.
Speaker Change: Or profitability goes and I have no reason to believe that 25 should be different.
Speaker Change: But I think it's also important to note the wherewithal and just look at last year, we started into the year with an EPS guidance of 210, we increased it three times. We ended it finished the year at $2 20, EPS guidance, while still keeping a very high level of R&D investments I do think that it's the way we look at our business.
Speaker Change: <unk>.
Dan Arias: The next question comes from Dan Arias with Stifel. Please go ahead.
Dan Arias: Thanks for the questions just digging a little bit about <unk> in the portfolio expansion here Rolling our theory I know its probably tough to compare because you launched the product and it's this weird post COVID-19 period that we're in here, but for the higher throughput Ks that rise instruments, how would you compare annualized.
Dan Arias: Pull through for that system in Europe to the mid throughput system.
Dan Arias: Once a customer is up and running and I ask just because I'm trying to understand.
Dan Arias: How the consumable stream might change here as the menu is built out and then the bigger question is can we think about.
Dan Arias: Overall consumables generation on Cai is that moving higher from an annualized pull through stand when is that something that you think happens as you push towards the end of the year.
Dan Arias: Well, it's a fair question that but the way I invite you to think about it is that anytime we think about.
Dan Arias: The chaos that rise.
Dan Arias: When you compare it with our normal carrier start.
Dan Arias: It's an equivalent of eight Ks that that's the way you should see it.
Dan Arias: And I'm not going to give numbers of pull through because it heavily depends on geographies and condition, but obviously.
Dan Arias: That help increasing one obviously the pull through per system.
Dan Arias: And second obviously devote human generated on carrier had consumables and regency's two today too.
Dan Arias: You showed that one of the.
Dan Arias: Impact on the improvement also on our per restaurant or efficiency improvement of the chaos that Costar group.
Dan Arias: Last but not least done that we'd insist on something.
Dan Arias: Why are you scared you start growing so fast above 20% and 24 after Nixon ensuring 'twenty free.
Dan Arias: Because it is by far the simplest instrument to use on the market.
Dan Arias: Between collecting the samples and putting the cast for each on their system, it's less than two minutes then.
Dan Arias: So imagine when you are.
Dan Arias: Implementing that efficiency and unique differentiation in higher throughput system.
Dan Arias: And this is why we are confident anytime we are bringing to rise into a high volume customers. They even more than normal customer see the significant workflow differentiation compared to competition.
Speaker Change: The next question comes from Dan Brennan with TD Cowen. Please go ahead.
Dan Brennan: Great. Thank you I thank for the questions.
Dan Brennan: Maybe I'll just ask the two rate here just on a P. P C R.
Speaker Change: You know you obviously called out the weaker instrument trends that were I guess, a corporate this year. If at all you know for the coming in below plan, but you also cited really strong placements I'm just could you help walk through.
Speaker Change: The 30% type growth that you're expecting for next year is that the second half instrument recovery is it pull through is it is it clinical so maybe some color on that.
Speaker Change: And then just be high level nothing from the new administration on EU import tariffs, but just any way to think about your exposure and you know to the extent, we see a 10 or 20% import tariff.
Speaker Change: And how do we think about the impact to guidance. Thank you.
Speaker Change: Thank you Dan so I'm going to start a we use a digital PCR kits to a question and I will ask for and also to share their views that we have explained already on the potential Terry's decision now in the U S had musician.
Speaker Change: Cause digital Pcr.
Speaker Change: When you look at 2024.
Speaker Change: Even if we acknowledge that capital sales whether it be tweak those.
Speaker Change: The growth coming from consumables is remarks keyboard.
Speaker Change: We are way above the double digit mark for the full year.
Speaker Change: And therefore, this will continue and what is fueling these.
Speaker Change: He is the progress we are making gave her yale by either increasing gas Hayes.
Speaker Change: Or developing new applications.
Speaker Change: 100, and USA for life Science and research in 2024.
Speaker Change: Development of solution for what we call the bio pharma.
Speaker Change: Application for cell and gene therapy.
Speaker Change: We said today that in December we launched that new increase flexing capabilities from five to 12 D. CS, giving you even more opportunities.
Speaker Change: In the pharma world and once again cell and gene therapies.
Speaker Change: We are launching now what does that mean to the clinical world we sum.
Speaker Change: Achievement in oncology and also offering that solution for labs, we seem to do L. G. T Laboratory developed tests.
Speaker Change: So D C is the vertical about where growth.
Speaker Change: Obviously.
Speaker Change: This will even be strengthened if we see as we said before a normalization of capital expenses in labs.
Speaker Change: In labs, but do not forget that in clinical World do you see is probably a solution that we we'd have to place riser.
Speaker Change: Rather than sell.
Speaker Change: And so indeed in life science, where we are mostly sell league.
Speaker Change: But an acceleration of capital says in H, two we'd help us achieving our target of her own costumes.
Speaker Change: Yeah, I do think there's a new administration desert.
Speaker Change: Most likely a lot of different impacts which are discussed in addressing run up some most likely one which is important for us is actually on a corporate tech side, because as you. All know we have a significant footprint in the U S. If not only a roughly a one 5% of our revenue a theory of auto is more or less the maggiore.
Speaker Change: You have our people in the meantime in U S. So any reduction in Trump's off corporate tax rates would be actually a beneficial for us, particularly in an environment, where the sofa was I have to play and there's an increasing tax rate. So I hope that it gets done.
Speaker Change: On the other hand of course are the tariff situation is very unclear, but I do think it's important that our people to differentiate it between and I know that it's not easy for people who are on the outside that there's a significant difference where you produce or where you create your values, particularly in industries like health care, where you have for example.
Speaker Change: P companies and others that might be sometimes in very different. So I do think it's really deep comes down to how the tariffs are structured and how things are getting implemented.
Speaker Change: Reducing clearly that we lead in a lot of different actions and interactions, but so far as hard to cut for us.
Speaker Change: The next question comes from Matt <unk> with Goldman Sachs. Please go ahead.
Matt: Thanks for taking my questions just two quick ones Terry first for you on <unk>. What is your expectation in terms of timing to get through that transition to SaaS from licenses and could we see an acceleration in growth in the second half of 2025, and maybe any commentary on a potential exit rate for that business and 25, and then Roland just on the margin expansion target how are you.
Speaker Change: Thinking about the level and phasing of Opex and twenty-five assuming R&D sticks around that 9% level. So specific on SG&A, how should we think about that over the course of the year. Thanks.
Speaker Change: This is Matt those are two very good questions. So first on QD either fishing is.
Speaker Change: We continue to believe in that market.
Speaker Change: You remember that we triggered an investment plan dedicated to <unk>.
Speaker Change: More than a year ago, we called it the Golden Gate investment plan, we are still investing in adding.
Speaker Change: Marketing capabilities sales capabilities.
Speaker Change: Product development capabilities and as I said during the presentation today.
Speaker Change: In neighborhood a solution.
Speaker Change: As we have been saying for the last.
Speaker Change: Four months.
Speaker Change: We see the transition.
Speaker Change: To the size of the business.
Speaker Change: Normalizing progressively starting H, two and impacting really our performance in 2026.
Speaker Change: And then I believe that he sees a gain.
Speaker Change: High single double D C I single digit market potential growth I'm, sorry potential low double digit.
Speaker Change: Okay.
Speaker Change: Yeah, just to follow on effect of all of this has been shown yet.
Speaker Change: Exactly just that the margin expansion I do think it's important to note that would be was so expect that we will actually see already a quite an increase here in the first quarter compared to a normal first quarter. So I wouldn't be surprised if or what do you see in the first quarter.
Speaker Change: The EBIT margin north of 28% and the wrong quickly into the direction, maybe even above the Saudi it already in the second quarter. So it's a very typical allocation H one H two.
Speaker Change: So therefore I would say.
Speaker Change: There's something what Roger is earlier.
Speaker Change: Then you probably would have planned for before.
Speaker Change: The next question comes from Casey Woodring with J P. Morgan. Please go ahead.
Casey Woodring: Great. Thank you guys for squeezing me in I'll, just ask two quickly attract so archives that you guys placed more than 660 instruments and 24 are following up on more than 700 placed in 'twenty. Three. So can you you can see continue to see strong placement demand post pandemic just curious what you expect for placements in 25, there gastro.
Speaker Change: <unk> approvals that unlocked new placement opportunities and then my second one is just can you touch on the re org.
Speaker Change: Two functional teams that are centered around product portfolio and innovation and then commercial operations just.
Speaker Change: What's the rationale there and what sort of incremental benefits do you expect to see from these moves in the near and longer term. Thank you.
Casey Woodring: Thank you Casey.
Casey Woodring: I think that taking into account my previous comment on always making sure that we are comparing April to Apple now that we are also accelerating the launches of our work I guess that rise anytime we put a rise you certainly equivalent at least of eight units on the normal cadence that should take this into account, but if we can be in that region.
Casey Woodring: Especially now that we have more menu in the U S with more than 600 systems per year I would be satisfied eats a good growth trajectory.
Casey Woodring: On the reorganization.
Speaker Change: At carriers and we do not believe that there is a bad all good organization.
Speaker Change: This company has been organized around business you need for many years and it served its purpose.
Speaker Change: We had a life science business unit.
Speaker Change: Our clinical diagnostic business unit and bioinformatics.
Speaker Change: We are just considering now that.
Speaker Change: That the market is changing I will customers are changing.
Speaker Change: In many sites.
Speaker Change: It's very difficult to define whizzer decosta Mary's pure year research or Easter kidney code in many many.
Speaker Change: Situations those are hybrid customers therefore for me being organized Gee.
Speaker Change: Into business unit was not the right way to answer our customer needs.
Speaker Change: And those are example.
Speaker Change: We said in New York.
Speaker Change: That beyond addressing needs.
Speaker Change: For life Science research and academia or for clinical.
Speaker Change: What qiagen dies.
Speaker Change: He's butadiene sustainable.
Speaker Change: Leading ecosystem.
Speaker Change: That are covering many needs.
Speaker Change: Needs in research needs in like in the academia needs in pharma needs in biotechs needs in the clinical labs also needs in crime investigation. For example, do you see is what we need mean by successful.
Speaker Change: Sustainable ecosystem.
Speaker Change: Sample take ease of clear ecosystem, you can give it to.
Speaker Change: Academy Club you can grieve it sure.
Speaker Change: Clinical labs digital PCR, Jean Paul tons for digital PCR, Okay, Yeah, Jed he's not waste time thinking should it be life science sort of clinical application what is important for us is to prove the value of.
Speaker Change: Digital PCR against for example, Q PCR or next generation sequencing and therefore, a company investment here makes sense.
Speaker Change: Lytton Shoebill ketosis, what is important is to push it beyond.
Speaker Change: Beyond just latent tuberculosis.
Speaker Change: If you look at chaos that it was mainly clinical now it's becoming also pharma added value solution because of the companion diagnostic.
Speaker Change: Agreement that we signed with astrazeneca or or or Eli Lilly. So this is where I invite you to see our priorities geez.
Speaker Change: And so the needs of our customers the merchant better.
Speaker Change: Yes.
Speaker Change: The last question comes from Hugo <unk> with BNP Paribas. Please go ahead.
Speaker Change: Hi, Hello, Thanks, Al like taking my questions I have a couple of follow ups are assessed on Pneumovax rollout, maybe can you give us the numbers are just heslin bill that you expect for 2025.
Speaker Change: That's my fault.
Speaker Change: On the 2028 targets a that'll be muscle one question can you maybe expand a bit on the on the vessel and incremental a.
Speaker Change: Margin progression that you can drive double digit growth beyond 2025, and I guess the trajectory sort of gross margin here. Thank you.
Speaker Change: I'm glad to see that your sort of your your I T shoes on the we'd have all our getting the second question on your magic She's very simple seat like these by 2025 H two the second half of the year, there shouldn't be any sales of our Ova and <unk>.
Speaker Change: And we expect a maximum revenues overall basically between eight to 10 million for 2025.
Speaker Change: What on the margin expansion.
Speaker Change: Yeah.
Speaker Change: The margin expansion as I said, there's a couple of drivers, which Oh I think we're just elaborate to even more on that and one which I think is very critical for US is there aren't Oh I T infrastructure under it's actually both at a sort of one side, our ERP system as you know in the middle of integrating or.
Speaker Change: It's a P system into the new S&P onto environment go from from farm to incidents through one global set up but at the same time of course, a significant digital infrastructure.
Speaker Change: No we have no roughly about 60% of our revenues coming in.
Speaker Change: Getting oh, that's handled fully Digitalized and we do believe you can expand on that as well and of course that has a significant impact to a company where 85% of the business.
Speaker Change: A very resilient consumable sales because they are very much for calling in and having a sales force who was our keen focus on lead generation instead of Whiting.
Speaker Change: Mostly are reordering for consumables is a big pain for a company like that I think the one thing we shouldn't underestimate is actually also the underlying trend for gross margin improvement because while I would say particular loss you are the larger part of some margin improvement.
Speaker Change: As a company on the EBIT level come from the operational side I do think that particular looking for but the significant incremental contribution comes from the gross margin side. One has to do with the mix, it's quite obvious that some of the diagnostic products grew faster than the.
Life Science products and typically you have.
Speaker Change: Somewhat higher gross margin contribution that here, but we also have some extra situations here.
Speaker Change: Most important for us as a volume cough on chaos Statics as you know, we clearly are still here not on the margin well. We believe we have anywhere close to what is the company ever extra days, So nice cool foster growth and there is much more volume golf would utilization stories than anything else.
Speaker Change: And of course, the portfolio expansion Hep C O lot because if you can use the same kind of production line for just having instead of two product four or five different topics that makes a significant difference.
Speaker Change: Another important topic for us that some of our instruments also have increasing gross margins are a. Good example is for example, cardiac Fujian cement that's an overdue believe they'll do a much better going forward and that is for example about ups in some of his which was a higher gross margin contribution. So I would say a lot of peace and getting up giving us the confidence.
Speaker Change: Overall margin improvement not only on the operational expense side, but also with gross margin.
Speaker Change: Contributions.
Speaker Change: This concludes our question and answer session. Please continue with any other points you wish to raise.
Speaker Change: Thank you operator.
Speaker Change: I'd like to thank all of you for your participation in the call and please keep in touch and contact Dominican me. If you have any questions bye bye.
Speaker Change: Ladies and gentlemen concludes the call.
Speaker Change: Carl Thank you for joining and have a pleasant day.
Speaker Change: [music].
Speaker Change: Yeah.
Speaker Change: [music].